Table 1.
Incidence of HER2 positivity in diverse cancers by IHC.
| Tumor Type | HER2 Positivity (%), Reported by Yan et al. [30] | HER2 Positivity (%), Reported by Other Studies |
|---|---|---|
| Bladder cancers | 12.4 | 16 [35] |
| Esophageal and esophagogastric junction cancers | 11.3 | 14.9 [36] |
| Breast cancers | 10.5 | 18.3 [37] |
| Gallbladder cancers | 9.8 | 11.11 [38] |
| Cholangiocarcinomas (extrahepatic) | 6.3 | 8.5 [39] |
| Gastric adenocarcinomas | 4.7 | 17.3 [40] |
| Cervical cancers | 3.9 | 1.5 [41] |
| Uterine cancers | 3 | 6 [42] |
| Testicular cancers | 2.4 | 5–8 [32] |
| Colorectal cancers | 1.8 | 2 [43] |
| Ovarian (epithelial) cancers | 1.6 | 8.16 [44] |
| Head and neck carcinomas | 1.3 | 4–19 [45,46] |
| Lung cancers (non-small cells) | 1.1 | 2.5 [47] |
| Intestinal (small) malignancies | 0.9 | 3 [48] |
| Pancreatic adenocarcinomas | 0.7 | 2 [49] |
| Cholangiocarcinomas (intrahepatic) | 0.6 | 4 [50] |
| Prostate cancers | 0.6 | 1.5 [51,52] |
| Hepatocellular carcinomas | 0.4 | 0 [53] |
| Ovarian (non-epithelial) cancers | 0.4 | 7.69 [54] |
| Melanomas | 0.1 | 0 [55] |
| Gastrointestinal stromal tumors | 0 | 0 [56] |
| Glioblastoma multiforme, high grade gliomas | 0 | 0 [57] |
| Kidney cancers | 0 | 2.3 [58] |
| Lung cancers (small-cells) | 0 | 13 [59] |
| Melanomas (uveal) | 0 | Not found |
| Neuroendocrine tumors | 0 | 0 [60] |
| Sarcomas (peritoneal, retroperitoneal) | 0 | Not found |
| Sarcomas (soft tissues) | 0 | 8 [61] |
| Thymic cancers | 0 | 0 [62] |
| Thyroid cancers | 0 | 0 [63] |
| Gliomas (low-grade) | 0 | 7 [57] |
| Oligodendrogliomas | 0 | Not found |
| Penile cancers | 0 | 0 [64] |
| Pituitary cancers | 0 | 5 [65] |
| Solitary fibrous tumors | 0 | Not found |
| Overall | 2.7 | Not found |